Singapore markets closed

Bio-Rad Laboratories, Inc. (BIO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
504.15+9.98 (+2.02%)
At close: 4:02PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 515.03B
Enterprise value 314.58B
Trailing P/E 7.82
Forward P/E 149.67
PEG Ratio (5 yr expected) 13.51
Price/sales (ttm)6.55
Price/book (mrq)2.03
Enterprise value/revenue 36.36
Enterprise value/EBITDA 635.64

Trading information

Stock price history

Beta (5Y monthly) 1.03
52-week change 351.51%
S&P500 52-week change 310.81%
52-week high 3540.06
52-week low 3309.38
50-day moving average 3507.95
200-day moving average 3458.21

Share statistics

Avg vol (3-month) 3183.85k
Avg vol (10-day) 3174.11k
Shares outstanding 524.59M
Float 21.19M
% held by insiders 114.29%
% held by institutions 179.15%
Shares short (14 Sep 2020) 4522.64k
Short ratio (14 Sep 2020) 42.8
Short % of float (14 Sep 2020) 42.44%
Short % of shares outstanding (14 Sep 2020) 41.76%
Shares short (prior month 13 Aug 2020) 4502.82k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 22:1
Last split date 307 Mar 2002

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2019
Most-recent quarter (mrq)29 Jun 2020

Profitability

Profit margin 84.89%
Operating margin (ttm)11.88%

Management effectiveness

Return on assets (ttm)1.92%
Return on equity (ttm)30.33%

Income statement

Revenue (ttm)2.29B
Revenue per share (ttm)76.92
Quarterly revenue growth (yoy)-6.20%
Gross profit (ttm)1.26B
EBITDA 408.98M
Net income avi to common (ttm)1.95B
Diluted EPS (ttm)64.50
Quarterly earnings growth (yoy)61.40%

Balance sheet

Total cash (mrq)1.03B
Total cash per share (mrq)34.77
Total debt (mrq)645.78M
Total debt/equity (mrq)8.78
Current ratio (mrq)2.30
Book value per share (mrq)247.77

Cash flow statement

Operating cash flow (ttm)414.48M
Levered free cash flow (ttm)339.8M